BMS 753
目录号 : GC14185A synthetic retinoid and RARα agonist
Cas No.:215307-86-1
Sample solution is provided at 25 µL, 10mM.
Ki : 2 nM for RARα
Three retinoic acid receptors (RARα, RARβ and RARγ and three retinoid X receptors, members of the nuclear receptor (NR) superfamily, mediate the biological effects of retinoic acids (all-tratis and 9-cis retinoic acids; t-RA and 9c-RA) upon development, cell differentiation and proliferation, and homeostasis. BMS 753 is identified as a RARα-selective agonist.
In vitro: Increasing concentrations of BMS 753 resulted in low levels of RARβ2 transcripts in WT cells, even at the highest concentration, while 100 nM BMS 753 efficiently induced RARβ2 transcripts in RARγ-/- cells. In contrast, no activation was seen in RARα-/- cells up to 100 nM BMS 753, demonstrating that it is specific for RARα [1].
In vivo: To investigate whether similar RARα-dependent events in Sertoli cells (SC) also operate in the reinitiation of spermatogenesis in a vitamin A-deficient (VAD) testis, Rbp4-null adult males fed a VAD diet for 14 wk were treated with BMS 753 or with its vehicle only. Interestingly, spermatogenesis did not initiate upon administration of BMS 753 to VAD Rbp4-null mutants; only SC and spermatogonia were present in their seminiferous epithelium, as in the vehicle-treated situation [2].
Clinical trial: Up to now, BMS 753 is still in the preclinical development stage.
Reference:
[1] RESHMA TANEJA, BIDYUT ROY, JEAN-Luc PLASSAT, CHRIS F. ZuSIt, JACEK OSTROWSKIS, PETER R. RECZEKS, AND PIERRE CHAMBON. Cell-type and promoter-context dependent retinoic acid receptor (RAR) redundancies for RARβ2 and Hoxa-1 activation in F9 and P19 cells can be artefactually generated by gene knockouts. Proc. Natl. Acad. Sci. USA Vol. 93, pp. 6197-6202, June 1996.
[2] Raverdeau M, Gely-Pernot A, Féret B, Dennefeld C, Benoit G, Davidson I, Chambon P, Mark M, Ghyselinck NB. Retinoic acid induces Sertoli cell paracrine signals for spermatogonia differentiation but cell autonomously drives spermatocyte meiosis. Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16582-7.
Cas No. | 215307-86-1 | SDF | |
化学名 | 4-(1,1,3,3-tetramethyl-2-oxo-2,3-dihydro-1H-indene-5-carboxamido)benzoic acid | ||
Canonical SMILES | CC(C1=C(C(C)2C)C=C(C(NC3=CC=C(C(O)=O)C=C3)=O)C=C1)(C2=O)C | ||
分子式 | C21H21NO4 | 分子量 | 351.4 |
溶解度 | <35.14mg/ml in ethanol; <35.14mg/ml in DMSO | 储存条件 | Store at RT |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.8458 mL | 14.2288 mL | 28.4576 mL |
5 mM | 0.5692 mL | 2.8458 mL | 5.6915 mL |
10 mM | 0.2846 mL | 1.4229 mL | 2.8458 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet